Cisplatin
Cisplatin 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Metastatic Non-small Cell Lung Cancer With MTAP Deletion、Intrahepatic Cholangiocarcinoma、Locally Advanced Non-Small Cell Lung Cancer (NSCLC)、Metastatic Non-Small Cell Lung Cancer (NSCLC)。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
5 项
已进入 III/IV 期
20 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- Bristol-Myers Squibb
- Francesco De Cobelli
- Revolution Medicines, Inc.
- National Cancer Institute (NCI)
- Memorial Sloan Kettering Cancer Center
- Sun Yat-sen University
- Fundación GECP
- Shanghai Kechow Pharma, Inc.
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
- WG Critical Care, LLC
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、西班牙、美国、比利时、法国、英国、Argentina、Chile、德国、Greece、Israel、意大利
正在招募患者的 Cisplatin 研究
Safety and Efficacy of Pucotenlimab in pLECC
II 期招募中中国NCT06969534Pathological Response After Neoadjuvant Treatment on NSCLC
不适用招募中西班牙NCT05167487Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
III 期招募中中国NCT06008106Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
II 期招募中中国NCT06088030Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC
II 期招募中中国NCT05738434Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma
不适用招募中中国NCT05595408Histotripsy in Biliary Tract Cancer
不适用招募中美国NCT07853690Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
早期 I 期招募中美国NCT05553782Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
II 期招募中美国NCT06745882Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma
III 期招募中中国NCT07177443Personalized Medicine for Advanced Biliary Cancer Patients
III 期招募中比利时法国英国NCT05615818Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers
III 期招募中法国NCT04747054A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
III 期招募中美国ArgentinaChile中国NCT07022483Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
不适用招募中中国NCT05892354Immediate Chemotherapy Following Resection for High-Risk Non-Muscle-Invasive Bladder Cancer
不适用招募中中国NCT06889623Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer
不适用招募中UkraineNCT07313579Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma
II 期招募中中国NCT06721286AB122 Platform Study
I 期招募中日本NCT04999761A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer
II 期招募中中国NCT07082179Paclitaxel-Bleomycin/Etoposide/Cisplatin vs Bleomycin/Etoposide/Cisplatin in Poor-prognosis Non-seminomatous Germ Cell Tumors (NSGCT) and Unfavorable Tumor Marker Decline
II 期招募中RussiaNCT07847190Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC
II 期招募中中国NCT07492342A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
II 期招募中中国NCT07622186A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
II 期招募中美国Argentina澳大利亚BrazilNCT07680764A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
I 期招募中中国NCT06181032
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。